02:23am Wednesday 23 August 2017

Scripps Research Institute Scientists Uncover New Compounds that Dynamically Alter Cell Signaling and Expand Options for Developing Breast Cancer Treatments

The study, published this week in the journal Nature Chemical Biology, focuses on compounds that interact with the estrogen receptor-α, a therapeutic target in breast cancer that causes widely varied effects, including cell proliferation, inflammatory activity and immune cell changes. The receptor, which binds to estrogens or similar molecules, is over-expressed in nearly three-quarters of breast cancer cases.

In the study, the scientists used a unique “structure class analysis” approach, making it far easier to identify broad structural patterns underlying how estrogen receptors bind to other molecules. In general, ligands—molecules that bind to a larger complex and trigger a reaction—bind in two distinct ways, either through a dynamic, changeable orientation or a single, constrained orientation. In the study, TSRI scientists compared a set of estrogen receptor ligands with dynamic binding orientation with those that bind in a single orientation.

“When you design a drug, you want a combination of effects that are beneficial,” said Kendall Nettles, a TSRI associate professor who led the study. “We discovered a new class of compounds that can bind to the receptor protein in two different orientations, flipping back and forth between the two. That shift can be used to give us specific signaling outcomes—anti-inflammatory, for example—far different from a ligand that binds in a single orientation.”

In this new analysis, estrogen receptor activity reflects an integration of a number of factors, any of which can alter the nuclear receptor’s signaling activity. In fact, the study establishes a novel principle in biology—that ligand dynamics can be exploited to control signaling specificity, a concept that could be applied more broadly in drug development.

The study also offers insight into environmental estrogens—such as Bisphenol A (BPA), an organic compound that has been in commercial use since 1957 to produce things like water bottles and sports equipment; BPA’s hormone-like properties have caused concern among consumers. The new study suggests a potential explanation as to why various environmental estrogens behave differently. “They all have different activity profiles and this mechanism could be one of the reasons,” Nettles said.

The first authors of the study, “Ligand Binding Dynamics Rewire Cellular Signaling via Estrogen Receptor-α” are Sathish Srinivasan and Jerome C. Nwachukwu of TSRI. Other authors include Valerie Cavett, Jason Nowak, Travis S. Hughes and Douglas J. Kinetin of TSRI; and John A. Katzenellenbogen of the University of Illinois. For more information on the paper, see http://www.nature.com/nchembio/journal/vaop/ncurrent/abs/nchembio.1214.html

The study was supported by the National Institutes of Health (PHS 5R37 DK015556; 5R33CA132022 and 5R01DK077085) and by Frenchman’s Creek Women for Cancer Research.

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world’s largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, TSRI has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute’s graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.

# # #

For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8136

Share on:


Health news